Highlights

  • 333D Ltd (ASX:T3D) operates across digital asset management, healthcare software development and 3D printing services.
  • Half-year Revenue to 31 December 2025 was $588,678, while the group reported a loss after tax of $282,030.
  • The company invested $150,000 in Firmus in June 2026 and continued development of its AI-enabled clinical software program.
  • March-quarter cash receipts from customers were $231,702, with positive net Operating Cash Flow of $71,505.

333D Ltd is an Australian technology company focused on the creation, management and monetisation of digital assets, with activities spanning healthcare software, AI-enabled file encoding and 3D printing services. During trading on October 7, 2026, 333D Ltd (ASX:T3D) was quoted at AUD 0.050, representing a 13.64% rise at the time of writing. The company is being reviewed against a backdrop of ongoing product development, Investment activity and changes in its operating cash profile during 2026.

Company Business

333D's operating model centres on digital content and data workflows. Its services include digital asset management, 2D and 3D content creation, healthcare software development and bespoke 3D printing. The company is also developing applications that use diagnostic and medical imaging data in DICOM format, with AI-based encoding used to create viewable 3D files. Revenue has been generated from digital asset management, healthcare software development and 3D printing services.

Healthcare software is a current development area. The company has been progressing software for dental and maxillofacial imaging applications, with the development pathway structured around technical and regulatory phases relevant to software-based medical devices.

Recent Development

In June 2026, 333D announced a $150,000 strategic investment in Firmus Grid Limited, an AI data-centre platform. The investment was funded from existing cash reserves and was described by the company as non-material, with no change to the nature of its activities. At the same time, 333D reported that its AI clinical-software development program had advanced through model-training work and was moving through pre-deployment optimisation and validation activities.

Earlier in 2026, the company reported improving operating cash movement in its March-quarter update. Customer receipts were $231,702 and net operating cash flow was positive at $71,505. Total cash and digital asset holdings were $1.022 million at quarter-end. The company later released further quarterly reporting in July and its Annual Report in August 2026.

Financial Performance and Sector Context

For the half-year ended 31 December 2025, revenue from ordinary activities increased to $588,678 from $480,497 in the prior corresponding period. The company reported a loss after income tax of $282,030, compared with a loss of $147,224 a year earlier. Net cash from Operating Activities was an inflow of $61,566, reversing the prior corresponding period's outflow of $292,681. Cash and cash equivalents at 31 December 2025 were $736,332.

The company's sector exposure combines software development, digital asset services and AI-related product development. These activities can require continuing spending on development, data access and regulatory work before Recurring Revenue is established. For 333D, the relationship between revenue, operating expenditure and available Liquidity remains an important financial consideration.

Risks to Consider

333D faces execution risk across product development and commercialisation. Healthcare software may require technical validation and regulatory processes before broader deployment, while revenue may vary between reporting periods because the Business remains relatively small. Digital asset holdings and the Firmus investment also introduce valuation and liquidity considerations. Funding requirements may remain relevant if operating expenditure exceeds internally generated cash flow.

What to Watch Next

Key matters to monitor include progress in the AI clinical-software program, commercial uptake across digital asset management and healthcare services, and operating cash flow. Future reporting should provide further information on customer receipts, expenditure and liquidity. Updates on the Firmus investment and healthcare software validation or regulatory milestones will also be relevant.

Key Insights

333D is pursuing a technology strategy centred on digital asset management, healthcare software and AI-enabled content processing. During 2026, the company reported higher half-year revenue, positive March-quarter operating cash flow and continued AI-related development. Commercial execution, liquidity and development spending remain central factors to monitor. The October 7, 2026 share-price move should therefore be considered alongside the company's reported operating and financial progress.